在接受一线化疗的扩散型大B细胞淋巴瘤患者中进行骨髓抑制的风险因子分析和诺莫грам的开发:双中心回顾性队列研究

Xuexing Wang1,2, Rong Zhang3, Haoling Xie1

  • 1Department of Oncology, Anning First People's Hospital Affiliated to Kunming University of Science and Technology, Kunming, Yunnan, China.

PeerJ
|June 23, 2025
PubMed
概括

这项研究确定了在接受化疗的扩散性大B细胞淋巴瘤 (DLBCL) 患者中肌肉抑制的关键风险因素. 开发了一个预测模型来评估骨髓抑制风险,帮助个性化DLBCL治疗策略.